GLAXO Stock Overview
Operates as a biopharma company in Pakistan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GlaxoSmithKline Pakistan Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨353.38 |
| 52 Week High | PK₨346.26 |
| 52 Week Low | PK₨75.01 |
| Beta | 0.27 |
| 11 Month Change | 65.99% |
| 3 Month Change | 134.48% |
| 1 Year Change | 286.59% |
| 33 Year Change | 152.02% |
| 5 Year Change | 97.51% |
| Change since IPO | 1,074.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| GLAXO | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | 11.6% | 1.9% | 2.1% |
| 1Y | 286.6% | 126.5% | 43.4% |
Return vs Industry: GLAXO exceeded the PK Pharmaceuticals industry which returned 126.5% over the past year.
Return vs Market: GLAXO exceeded the PK Market which returned 43.4% over the past year.
Price Volatility
| GLAXO volatility | |
|---|---|
| GLAXO Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in PK Market | 9.6% |
| 10% least volatile stocks in PK Market | 3.8% |
Stable Share Price: GLAXO's share price has been volatile over the past 3 months compared to the PK market.
Volatility Over Time: GLAXO's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of PK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,700 | Erum Rahim | www.pk.gsk.com |
GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan and internationally. It deals in anti-infective, dermatology, respiratory, analgesics, immunology, oncology, urology, HIV, vaccines, and analgesics therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Cutivate, Calpol, Boostrix, Rotarix, Havrix, and Synflorix.
GlaxoSmithKline Pakistan Limited Fundamentals Summary
| GLAXO fundamental statistics | |
|---|---|
| Market cap | PK₨102.31b |
| Earnings (TTM) | PK₨4.51b |
| Revenue (TTM) | PK₨56.23b |
25.0x
P/E Ratio2.0x
P/S RatioIs GLAXO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLAXO income statement (TTM) | |
|---|---|
| Revenue | PK₨56.23b |
| Cost of Revenue | PK₨45.90b |
| Gross Profit | PK₨10.33b |
| Other Expenses | PK₨5.83b |
| Earnings | PK₨4.51b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.15 |
| Gross Margin | 18.38% |
| Net Profit Margin | 8.01% |
| Debt/Equity Ratio | 0% |
How did GLAXO perform over the long term?
See historical performance and comparison